0001209191-23-018571.txt : 20230314 0001209191-23-018571.hdr.sgml : 20230314 20230314175019 ACCESSION NUMBER: 0001209191-23-018571 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230314 FILED AS OF DATE: 20230314 DATE AS OF CHANGE: 20230314 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Prasad Raju CENTRAL INDEX KEY: 0001968317 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37923 FILM NUMBER: 23732310 MAIL ADDRESS: STREET 1: CRISPR THERAPEUTICS, INC. STREET 2: 105 W FIRST STREET CITY: BOSTON STATE: MA ZIP: 02127 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CRISPR Therapeutics AG CENTRAL INDEX KEY: 0001674416 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 473173478 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 BUSINESS PHONE: 6173154600 MAIL ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-03-14 0 0001674416 CRISPR Therapeutics AG CRSP 0001968317 Prasad Raju C/O CRISPR THERAPEUTICS, INC. 105 WEST FIRST STREET BOSTON MA 02127 0 1 0 0 Chief Financial Officer Restricted Stock Units 2023-03-14 4 A 0 40000 0.00 A Common Shares 40000 40000 D Stock Option (Right to Buy) 45.15 2023-03-14 4 A 0 100000 0.00 A 2033-03-14 Common Shares 100000 100000 D Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. This restricted stock unit award was granted on March 14, 2023 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on March 14, 2024, (ii) one quarter of the shares vesting on March 14, 2025, (iii) one quarter of the shares vesting on March 14, 2026, and (iv) one quarter of the shares vesting on March 14, 2027. This option was granted on March 14, 2023 with respect to 100,000 Common Shares, with 25% of the shares vesting on March 14, 2024 and the remaining shares vesting on each monthly anniversary thereafter for a period of 36 months. /s/ Elizabeth Ryland Waldinger, attorney-in-fact 2023-03-14